Skip to main content
Premium Trial:

Request an Annual Quote

Gyros Announces $20 Million in Third Round Funding

NEW YORK, Dec. 17 (GenomeWeb News) -- Gyros of Uppsala, Sweden, said today that it has taken in $20 million from existing investors in a third round of financing.

 

The funding was led by Scandinavian Life Science Venture (SLSV) and included Investor Growth Capital, Schroder Ventures Life Sciences, 3i, Ettena Förvaltnings AB (formerly SIF), the Swedish Industrial Development Fund, InnovationsKapital, Health & Brand Capital, and Life Equity Sweden.

 

Gyros is commercializing a system designed to automate sample prep for MALDI mass spectrometry and boost sensitivity in protein identification. It is a new application of the company's core platform, by which laboratory processes are miniaturized and embedded into CDs for parallel preparation and processing.

 

Gyros was spun off from Amersham Pharmacia Biotech in 2000.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.